This study was initiated to evaluate the long-term safety, tolerability and effect on seizure control of lamotrigine (Lamictal@) in paediatric patients with epilepsy. A total of 155 children (aged 2-19 years) with treatment-resistant epilepsy received add-on therapy or monotherapy lamotrigine for up to four years. Patients had already experienced benefit from lamotrigine treatment in an open one-year study before entering this open continuation study of up to three additional years of treatment. Overall, including both these studies, patients were treated with lamotrigine for 53-221 weeks, representing 417.9 patient-years of experience. The physician's global assessment of seizure control compared to the three-month period before lamotrigine treatment, indicated that seizure control was generally maintained during long-term lamotrigine treatment for up to four years. For 19 patients, the investigator recorded a subjective improvement in behaviour, alertness, seizure severity, quality of life and mobility with lamotrigine treatment, sometimes independent of seizure control. In total, 34 patients received lamotrigine monotherapy; 22 of these were maintained on lamotrigine monotherapy for at least one year. Lamotrigine was well tolerated. The majority of adverse experiences were classified by the'physician as being mild in intensity and only six patients (4%) withdrew from the study due to adverse experiences.
INTRODUCTION

Lamotrigine
(Lamictal@) is a broad-spectrum antiepileptic drug (AED) which acts primarily via a use-dependent blockade of voltage-sensitive sodium channels' to stabilize the neuronal membrane and inhibit the release of excitatory neurotransmitters, principally glutamate. Lamotrigine is effective as add-on therapy in adults with refractory partial and secondarily generalized tonic-clonic seizures2V3 and has been shown to be at least as effective as carbamazepine4 or phenytoin5, but better tolerated when used as monotherapy in newly-diagnosed patients with epilepsy .
4*s In addition, lamotrigine has demonstrated efficacy in paediatric patients with treatment-resistant partial, myoclonic, absence, tonic and atonic seizures in trials lasting up to 12 monthsGg. In view of the need for prolonged treatment of patients with epilepsy, it is important that the efficacy and tolerability of any AED is maintained during long-term therapy. In this continuation study, the long-term safety and efficacy of lamotrigine were evaluated in paediatric patients who had already completed a 12-month trial of lamotrigine as add-on therapy and who had shown benefit with acceptable tolerability in the initial study. The results of the initial 1Zmonth study have recently been publishedg. Some patients in the continuation study received lamotrigine monotherapy as a result of the successful withdrawal of previously prescribed AEDs. Besag et al refractory epilepsy treated successfully with lamotrigine with or without other AEDs, were included in an international multicentre open continuation study of lamotrigine therapy. To be included, patients must have benefited from treatment with lamotrigine, with no unacceptable adverse experiences, during the previous 12-month open study. There were 155 patients from 32 centres who received lamotrigine for up to an additional three years in this continuation study.
The parent or guardian of the child had given written informed consent for participation in the initial 1Zmonth study with the understanding of the availability of a continuation phase should the child benefit from continued lamotrigine treatment. The study was approved by local ethics committees and was conducted in accordance with the declaration of Helsinki.
Study design
The screening visit for the continuation study generally utilized data from the last visit of the previous 1Zmonth
trial. The daily dose of lamotrigine was the optimal dose determined individually for each patient in the previous 1Zmonth study and was, in the first case, based on the patient's concurrent antiepileptic medication. The dose of lamotrigine was adjusted as required to improve efficacy or reduce any adverse effects. A twice-daily dosage regimen was generally used and, where possible, each dose consisted of a single tablet or capsule.
There was no restriction to the number of concomitant AEDs used. Dosage reduction or withdrawal of co-medication was allowed, with appropriate adjustments to the lamotrigine dose where necessary.
In this study, the final evaluation was carried out after either two or three years of additional treatment with lamotrigine.
Alternatively, participation in the continuation study ceased when the patient met certain withdrawal criteria. These were: withdrawal of informed consent by the parent or guardian; development of severe or unacceptable adverse experiences (including biochemical or haematological abnormalities); lack of efficacy or any risk outweighing benefit from continued lamotrigine treatment; or evidence of serious non-compliance.
In many cases, the decision was made to continue treatment with lamotrigine.
If lamotrigine was discontinued, it was recommended that the dose was reduced to 50% for two weeks and then to 25% for a further two weeks before finally stopping treatment. This was to decrease the likelihood of rebound seizures occurring.
Assessment procedures
The medical history of each patient had already been documented for the previous 1Zmonth study'. This included details of seizure aetiology, type and frequency, age at first seizure, and the occurrence of status epilepticus. For each patient, demographic data were recorded, detailing date of birth, sex, height and weight. Standard physical and neurological examinations, including fundoscopy were performed. In addition, haematological and biochemical assessments were conducted.
Patients entering the continuation study after completing 48 weeks of lamotrigine therapy were seen at approximately six-month intervals, at weeks 72,96, 120, 144, 168 and 192 when seizure frequency, adverse experiences, height, weight, lamotrigine compliance and concurrent AED compliance were evaluated. The week numbers refer to the total weeks of treatment with lamotrigine, from the commencement of therapy and not from the commencement of the continuation study. This implies that the first week of the study was after 48 weeks of lamotrigine therapy, that is after approximately one year.
Seizure frequency was compared to a threemonth historical baseline prior to lamotrigine treatment and was assessed on a scale of 1 to 7: 1 = marked deterioration; 2 = moderate deterioration; 3 = mild deterioration; 4 = no change; 5 = mild improvement; 6 = moderate improvement; 7 = marked improvement. The total daily dose of lamotrigine over the previous two weeks and the dosage reduction or withdrawal of concomitant AED were recorded. Compliance with taking lamotrigine was recorded as excellent (100% compliance), good (SO-90%), poor (50-79%), unacceptable (~50%) or unknown. The assessment was made by the investigator by discussion with the parent or guardian and by counting the returned capsules.
Adverse experiences since the last documented visit were recorded with respect to intensity, seriousness, action taken and whether they were attributable to lamotrigine. Intensity was reported as mild, moderate or severe. Seriousness was classified as non-serious, serious or lifethreatening. Each event was allocated to one of three categories: attributable to lamotrigine, not attributable to lamotrigine, or unknown. Action taken was reported as none required, change in the study drug, treatment required or other.
Other safety data were assessed at weeks 96, 144 and 192. These included laboratory measurements of haematological function (white blood cell count, haemoglobin, mean corpuscular volume, platelets) and biochemistry (urea, creatinine, total protein, albumin, alanine aminotransferase and/or aspartate aminotransferase, bilirubin) and other safety data such as physical and neurological examinations, including fundoscopy.
RESULTS
Patient population
A total of 155 patients (91 male, 64 female) entered the continuation study. At the start of the continuation study, 21% of the patients were aged 2 to ~6 years, 59% were aged 6 to ~13 and 21% were 213 years (up to a maximum of 19 years). From the physical and neurological examinations at the screening visit, 37% of patients had some degree of developmental impairment.
Treatment
A summary of the duration of lamotrigine treatment is given in Table 1 . Overall, 155 patients were treated with lamotrigine for 52-221 weeks, of which 89 patients received lamotrigine for at least 144 weeks (including treatment in the initial study). The mean duration of treatment was 140 weeks. This represents 417.9 patientyears of experience.
At the start of the continuation study, 57 patients were taking one concomitant AED, 71 were taking two, four were taking three, and one (6) ll (7) 10 (6) 3.5 (23) ll (46) 18 (12) patient was taking four AEDs. Twenty-two patients were on lamotrigine monotherapy at entry into the continuation study.
Study completion
Of the 155 patients who entered the continuation study, 109 (70%) were considered to have completed the study, having been treated to either week 192 (14 patients) or week 144 (95 patients). Of the 46 patients who discontinued prematurely, 21 patients withdrew due to lack of continuing benefit, six due to adverse experiences and the remaining 19 due to a variety of other reasons.
Global seizure control
The overall percentage of patients with an improvement in seizure control compared with the original baseline (category 5, 6 or 7) was maintained throughout the continuation study, being 80% (110/137) at week 72,76% (93/122) at week 96, 76% (90/119) at week 120 and 73% (66/91) at week 144 (Fig. 1 ). There were fewer patients .at week 168 because only one centre could continue lamotrigine treatment beyond week 144, but 89% (24/27) of these patients had an improvement in seizure control. Patients with no change in their seizure frequency accounted for 12% (16/137), 12% (15/122), 16% (19/119), 23% (21/91) and 11% (3/27) patients at weeks 72, 96, 120, 144 and 168, respectively. The proportion of patients with any deterioration (category 1,2 or 3) in seizure frequency was low, being between 5 and 11% throughout the continuation study. \ For 19 patients, the investigator recorded subjective comments regarding seizure control. These comments indicated beneficial effects of lamotrigine treatment on behaviour, alertness, seizure severity, quality of life and mobility. Some of these reports were in patients where lamotrigine treatment was continued in the absence of a significant effect on seizure frequency. of lamotrigine in each patient subgroup. In the 68 patients who received AED co-medication which did not include sodium valproate, 5-15 mg/kg/day might be considered to be the optimum daily dose of lamotrigine, because the minimum and maximum dosages were within this range in the majority of patients (66 and 74%, respectively). This is in comparison to a likely optimum daily lamotrigine dose of approximately l-5 mg/kg/day in patients receiving a concomitant AED regimen which included sodium valproate, because this was the minimum and maximum dosage in 56 and 47% of patients, respectively. However, 27 (42%) of patients taking concomitant sodium valproate had a maximum lamotrigine dose of >5 mg/kg/day. There was no evidence that either concomitant AEDs or weight changes during the study were responsible for the high number of patients in this group.
At least one AED was withdrawn from the medication of 30 patients during the study and in 14 cases this resulted in a permanent reduction in the number of AEDs. Four of these patients were maintained on lamotrigine monotherapy and a further eight patients were treated with lamotrigine monotherapy at some time. Of the 22 patients who entered the continuation study on lamotrigine monotherapy, 13 remained so throughout the duration of the study. In total, 34 patients received lamotrigine monotherapy during the continuation study. Eighteen of these received lamotrigine monotherapy for at least one year and a further four patients were treated with lamotrigine monotherapy for at least three years.
The majority of patients were considered to have excellent compliance with the lamotrigine dosage regimen at each scheduled evaluation period of the study. The proportion of patients assessed as being 100% compliant ranged from 81% (at week 144) to 89% (at weeks 48, 96 and 168).
Adverse experiences and safety evaluation Eighty-three patients (54%) reported 176 adverse experiences after the screening visit for the continuation study. Twelve adverse experiences were reported by more than three patients (Table  2) in the continuation study. The majority (63%) of adverse experiences were classified as being mild in intensity.
Only six patients (4%) withdrew from the study because of an adverse experience. These were: persistence of a rash which had developed during the initial study; aggression and confusion; (14) 13 (8) 8 (5) 7 (5) 7 (5) 6 (4) Rhinitis 6 (4) Headache 5 (3) Rash 5 (3) Vomiting 5 (3) Accidental injury 4 (3) Abdominal pain 4 (3) * Aggravated reaction includes increased seizure frequency or severity, prolonged seizures and status epilepticus. t Unevaluable reaction refers to experiences which could not be coded and were hospitalization for oximetry; irritability; decreased mobility; dental treatment: bilateral femoral rotation osteotomy; increase of mucous; increase of mucous secretion; callosotomy; and adrenotonsillectomy. moderate paraesthesia in the legs; an increase in seizures; death attributed to sudden unexplained death in epilepsy (SUDEP);
and death shortly after a seizure thought to be due to aspiration of gastric contents. Only the rash was considered, by the investigator, to be related to lamotrigine treatment, in the other cases the causality was considered to be either not related (two cases) or unknown (three cases).
Lamotrigine had no effect on the distribution of height and weight measurements throughout either the initial 12-month study or the subsequent continuation study (Tables 3 and 4) . No physical or neurological abnormalities occurred during the continuation study which had not been reported at the screening visit. There were no clinically significant abnormal laboratory test results. DISCUSSION 
AND CONCLUSIONS
The clinical efficacy of lamotrigine as add-on therapy for treatment-resistant epilepsy in children has previously been demonstrated in open 12-month studies in patients with a broad range of seizure typesG9. In this continuation study, the long-term efficacy of lamotrigine was assessed by a global evaluation of seizure control given by the investigator relative to the period prior to initiation of lamotrigine therapy. Although less objective than seizure counts, global assessments are more clinically appropriate for long-term analyses in view of the difficulty in continuing to count seizures on a daily basis over long periods of time. In the initial 1Zmonth study, global evaluations of seizure control showed that 69% of patients had an improvement at week 12 and 74% at week 48'. In this continuation study, this level of seizure control was maintained. Improvement in seizure control relative to a three-month period prior to initiation of lamotrigine therapy was achieved in 80% of patients after 72 weeks of treatment and this was generally maintained, with 73% of patients assessed as having an improvement after 144 weeks of lamotrigine treatment. 13 (9) 15 (13) ll(l4) 63 (41) 68 (45) 55 (43) 34 (41) 53% 17 (11) 19 (12) 17 (14) 11 (13) Few patients withdrew from the study due to lack of continuing benefit, suggesting that lamotrigine provides good long-term maintenance of seizure control. It is noteworthy that the long-term maintenance of seizure control was achieved in a population of children with relatively severe epilepsy.
Pharmacokinetic studies in children, as in adults, show that the rate of elimination of lamotrigine is influenced by some AEDs'. The recommended maintenance doses of lamotrigine in children receiving other AEDs including (l-5 mg/kg/day) or excluding (5-15 mg/kg/day) sodium valproate" were confirmed during this study. The dose of lamotrigine was adjusted as required in order to maximize efficacy or minimize adverse experiences. In almost half of the patients taking sodium valproate, this resulted in a daily lamotrigine dose of >5 mg/kg/day. There was no evidence of any relationship between the lamotrigine dose and any additional AED in the group receiving sodium valproate (that is the presence or absence of any hepatic enzymeinducing drugs). This suggests that further improvements in seizure control may be obtained with higher doses of lamotrigine.
There was no evidence of an increase in the required maintenance dose of lamotrigine in the long-term.
Long-term tolerability of AEDs in children is important, because the adverse event profile of the drug is often a major determinant in the choice of therapy". This continuation study has shown that the favourable safety profile of lamotrigine that was observed in the initial 1Zmonth study' is maintained in the long-term. As in previous studies in children, the most common adverse experiences included an increase in frequency or severity of seizures (aggravated reactions) and typical childhood illnesses, particularly infections. These are consistent with the expected fluctuations in seizure control and general health of this population of paediatric patients with treatment-resistant epilepsy. There was no evidence of the emergence of adverse intellectual or cognitive effects as a result of lamotrigine therapy. Indeed, several investigators spontaneously reported subjective improvements in alertness, behaviour, seizure severity, quality of life and mobility in a number of children in this study. This is consistent with previously published observations in children taking lamotrigine12. In addition, lamotrigine did not appear to affect normal growth.
Non-compliance with AEDs, often as a result of side-effects, is considered to be one of the main causes of treatment failure13. Lack of compliance with AED therapy has been reported in as many as 2575% of paediatric patients". The high degree of compliance observed in this study and the low rate of withdrawal due to adverse experiences appear to confirm the good long-term tolerability of lamotrigine.
In conclusion, seizure control was maintained for up to a total of four years of treatment with lamotrigine in paediatric patients with treatmentresistant epilepsy. Lamotrigine was we11'tolerated during long-term therapy with the majority of adverse experiences being mild in intensity and not necessitating the withdrawal of lamotrigine therapy. There was no evidence of any deleterious effect on the growth of the children.
